Center for Cell Engineering Seventh Annual Retreat


Celebrating the Opening of the Michael G. Harris Cell Therapy and Cell Engineering Facility


Refreshments will be served at 1:45 pm.


This program is for the research community.


SESSION I: STEM CELL THERAPY, 2:00 pm - 3:30 pm

Cell Therapy for Parkinson’s Disease

Lorenz Studer, MD
Director, Center for Stem Cell Biology
Developmental Biology Program, MSK

Clinical Cord Blood Transplantation: Current State of the Art

Juliet N. Barker, MBBS
Director, Cord Blood Transplantation Program
Department of Medicine, MSK

Pluripotent-independent Reprogramming of Endothelial to Hematopoietic Cells by Vascular Induction

Shahin Rafii, MD
Director, Ansary Center for Stem Cell Therapeutics
Weill Cornell Medical College

Globin Gene Transfer for Thalassemia and Sickle Cell Disease

Farid Boulad, MD
Medical Director, Pediatric Day Hospital
Department of Pediatrics, MSK

SESSION II: T CELL THERAPY, 3:30 pm - 5:30 pm

CAR T Cells

The Many Roles of the Cell Therapy and Cell Engineering Facility

Isabelle Rivière, PhD
Director, Cell Therapy and Cell Engineering Facility
Molecular Pharmacology & Chemistry Program, MSK

CD19 CAR T Cell Therapy

Renier Brentjens, MD, PhD
Director, Cellular Therapeutics Center
Department of Medicine, MSK

Mesothelin CAR T Cell Therapy

Prasad S. Adusumilli, MD, FACS
Deputy Chief, Thoracic Service
Department of Surgery, MSK

Enhancing the IQ of CAR T Cells Using the Synthetic Biology Tool Box

Michael Jensen, MD
Director, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Hospital
University of Washington

The Design of Receptors and Cell Products for Cancer Immunotherapy

Stanley Riddell, MD
Member, Fred Hutchinson Cancer Research Center
University of Washington School of Medicine

TCR T Cells

Engineering T Cells to Target Oncogenic Proteins: It Starts with the TCR

Philip Greenberg, MD
Head, Immunology Program, Fred Hutchinson Cancer Research Center
University of Washington School of Medicine

Adoptive Immunotherapy with Transplant Donor or Third Party-derived EBV-specific T-cells for EBV-associated Malignancies

Richard O’Reilly, MD
Chair, Department of Pediatrics
Chief, Pediatric Bone Marrow Transplant Service, MSK


Michel Sadelain, MD, PhD
Director, Center for Cell Engineering
Immunology Program, MSK

View agenda as a PDF

Date & Time(s)


Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
ZRC Auditorium
New York, NY 10065